Treatment with the ATG4B inhibitor significantly reduced the AML (GFP+) cell population in the peripheral blood and extended the survival of AML model mice (Figure 7C; Figure S6C, Supporting Information). Here, ATG4B is linked to acute myeloid leukemia.